Salvia Polyphenolates Combined with Doxophylline in the Treatment of Patients with Chronic Pulmonary Heart Disease in the Compensated Stage  

作　　者：Meijuan Ma Fen Yang 

机构地区：[1]Shaanxi Provincial People’s Hospital Cadre Physical Examination Center,Xi’an 710068,Shaanxi Province,China [2]Department of Respiratory and Critical Care Medicine,Shaanxi Provincial People’s Hospital(Xixian),Xi’an 710068,Shaanxi Province,China

出　　处：《Journal of Clinical and Nursing Research》2024年第5期52-55,共4页临床护理研究（英文）

摘　　要：Objective:To statistically determine the effect of salvia polyphenolates combined with doxophylline treatment in patients with chronic pulmonary heart disease in the compensated stage.Methods:From January 2023 to January 2024,76 patients with chronic pulmonary heart disease in the compensated stage were selected as research subjects.The patients were divided into a research group and a reference group using a randomized numerical table method.The research group was treated with salvia polyphenolates combined with doxophylline,while the reference group received conventional therapy.The treatment effects of the two groups were compared.Results:The patients in the research group,treated with salvia polyphenolates combined with doxophylline,showed maximal ventilation of 73.26±4.83 L/min,left ventricular ejection fraction of 56.14±1.98%,and total effective treatment rate of 94.74%.These results were better than those of the reference group.The differences between the data of the research group and the reference group were statistically significant(P<0.05).Conclusion:For patients with chronic pulmonary heart disease in the compensated stage,treatment with salvia polyphenolates combined with doxophylline significantly improves maximum ventilation and left ventricular ejection fraction,and also results in a higher total effective treatment rate.

关 键 词：Salvia polyphenolates Doxophylline Chronic pulmonary heart disease in the compensated stage 

分 类 号：R73[医药卫生—肿瘤]